Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751

Manufacturer: AbbVie
Regulatory submission: NDA submitted September 2025
Launch: Expected by Citi analysts in the third quarter of 2026
Last updated: October 1, 2026

Section

Product information and disease description Product description Product information

Drug/Drug, drug/disease interactions

14 evidence topics · 3 sources